2024 | Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study | Passaro, A; Wang J.; Wang, Y; Lee, S-H; Melosky, B; JIN-YUAN SHIH ; Azuma, K; Juan-Vidal, O; Cobo, M; Felip, E; Girard, N; Cortot, A B; Califano, R; Cappuzzo, F; Owen, S; Popat, S; Tan, J-L; Salinas, J; Tomasini, P; Gentzler, R D; William, W N; Reckamp, K L; Takahashi, T; Ganguly, S; Kowalski, D M; Bearz, A; MacKean, M; Barala, P; Bourla, A B; Girvin, A; Greger, J; Millington, D; Withelder, M; Xie, J; Sun, T; Shah, S; Diorio, B; Knoblauch, R E; Bauml, J M; Campelo, R G; Cho, B C | Annals of oncology : official journal of the European Society for Medical Oncology | 17 | | |